onr:"swepub:oai:DiVA.org:uu-280259"
Sökning: onr:"swepub:oai:DiVA.org:uu-280259" > Long-term immunogen...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04655naa a2200481 4500 | |
| 001 | oai:DiVA.org:uu-280259 | |
| 003 | SwePub | |
| 008 | 160309s2016 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2802592 URI |
| 024 | 7 | a https://doi.org/10.1016/j.vaccine.2015.09.0732 DOI |
| 040 | a (SwePub)uu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Chlibek, Romanu Univ Def, Fac Mil Hlth Sci, Hradec Kralove, Czech Republic.4 aut |
| 245 | 1 0 | a Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults |
| 264 | 1 | b Elsevier BV,c 2016 |
| 338 | a electronic2 rdacarrier | |
| 520 | a Background: An investigational subunit vaccine containing the varicella-zoster virus (VZV) glycoprotein E (gE) and the AS01(B) adjuvant system is being evaluated for the prevention of herpes zoster (HZ) in older adults. A phase II trial evaluating different formulations of this vaccine (containing 25 mu g, 50 mu g, or 100 mu g gE) was conducted in adults >= 60 years of age and showed that all formulations elicited robust cellular and humoral immune responses for up to 3 years after vaccination. In this follow-up study in subjects who received two doses of the 50 mu g gE/AS01(B) formulation (HZ/su), we assessed the persistence of the immune responses for up to 6 years after vaccination. Methods: This phase II, open-label, multicenter, single-group trial conducted in the Czech Republic, Germany, Sweden, and the Netherlands followed 129 subjects who had received two doses (2 months apart) of HZ/su during the initial trial. Vaccine-induced immune responses (frequencies of gE-specific CD4(+) T cells expressing >= 2 activation markers and serum anti-gE antibody concentrations) were evaluated at 48, 60, and 72 months after the first HZ/su dose. Results: Six years after vaccination with HZ/su, gE-specific cell-mediated immune responses and anti-gE antibody concentrations had decreased by 20-25% from month 36, but remained higher than the prevaccination values. At month 72, the gE-specific cell-mediated immune response was 3.8 times higher than the prevaccination value (477.3 vs. 119.4 activated gE-specific CD4(+) T cells per 10(6) cells), and the anti-gE antibody concentration was 7.3 times higher than the prevaccination value (8159.0 vs. 1121.3 mIU/mL). No vaccine-related serious adverse events were reported between months 36 and 72. Conclusions: gE-specific cellular and humoral immune responses persisted for 6 years after two-dose vaccination with HZ/su in healthy older adults. No safety concerns were identified. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng |
| 653 | a Varicella-zoster virus | |
| 653 | a Glycoprotein E | |
| 653 | a Subunit vaccine | |
| 653 | a lmmunogenicity | |
| 653 | a Persistence | |
| 700 | 1 | a Pauksens, Karlisu Uppsala universitet,Infektionssjukdomar4 aut0 (Swepub:uu)karlpauk |
| 700 | 1 | a Rombo, Larsu Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Univ Hosp, Dept Med, Stockholm, Sweden.4 aut0 (Swepub:uu)larra728 |
| 700 | 1 | a van Rijckevorsel, Giniu Publ Hlth Serv Amsterdam, Dept Infect Dis, Amsterdam, Netherlands.4 aut |
| 700 | 1 | a Richardus, Jan H.u Municipal Publ Hlth Serv Rotterdam Rijnmond, Rotterdam, Netherlands.4 aut |
| 700 | 1 | a Plassmann, Georgu Unterfrintroper Hausarztzentrum, Essen, Germany.4 aut |
| 700 | 1 | a Schwarz, Tino F.u Stiftung juliusspital, Cent Lab, Wurzburg, Germany.;Stiftung juliusspital, Vaccinat Ctr, Wurzburg, Germany.4 aut |
| 700 | 1 | a Catteau, Gregoryu GSK Vaccines, Wavre, Belgium.4 aut |
| 700 | 1 | a Lal, Himalu GSK Vaccines, King Of Prussia, PA USA.4 aut |
| 700 | 1 | a Heineman, Thomas C.u GSK Vaccines, King Of Prussia, PA USA.4 aut |
| 710 | 2 | a Univ Def, Fac Mil Hlth Sci, Hradec Kralove, Czech Republic.b Infektionssjukdomar4 org |
| 773 | 0 | t Vaccined : Elsevier BVg 34:6, s. 863-868q 34:6<863-868x 0264-410Xx 1873-2518 |
| 856 | 4 | u https://doi.org/10.1016/j.vaccine.2015.09.073y Fulltext |
| 856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:910457/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
| 856 | 4 | u https://doi.org/10.1016/j.vaccine.2015.09.073 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-280259 |
| 856 | 4 8 | u https://doi.org/10.1016/j.vaccine.2015.09.073 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Chlibek, Roman
- Pauksens, Karlis
- Rombo, Lars
- van Rijckevorsel ...
- Richardus, Jan H ...
- Plassmann, Georg
- visa fler...
- Schwarz, Tino F.
- Catteau, Gregory
- Lal, Himal
- Heineman, Thomas ...
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Medicinska och f ...
- och Immunologi inom ...
- Artiklar i publikationen
- Vaccine
- Av lärosätet
- Uppsala universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
